ClinicalTrials.gg
CompletedNCT00566501Updated Nov 17, 2021Results posted

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

A Phase 3 interventional study of Donepezil in Alzheimer's Disease, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 45 Years to 91 Years. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
915
Allocation
Non-randomized
Ages
45 Years to 91 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
2nd of 58
915 · median 79
Started
2007
with 4 others
Phase 3
10 of 60
1 open now
Registered
20th of 60
by date
Lead sponsor
9 of 60
Eisai Inc.

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 2nd largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 10 in phase 3, and was the 20th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 45 Years to 91 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of long-term administration of 23 milligram (mg) donepezil sustained release (SR) in participants with moderate to severe Alzheimer's disease. Participants who complete study E2020-G000-326 (NCT00478205) with no ongoing serious adverse events (SAEs) and no serious adverse drug reactions will be eligible to enter the open-label extension study.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Moderate-to-severe
  • Alzheimer's
  • Disease
04

Who can participate

Ages eligible
45 Years to 91 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Participants:

  1. Written from the participant (if possible) or from the participant's legal guardian or other representative at the time of the Baseline visit, prior to beginning any assessments or activities.
  2. Completion of study E2020-G000-326 (NCT00478205) without ongoing SAEs or history of serious adverse drug reactions during study E2020-G000-326 (NCT00478205).
  3. Participant must enroll in the present study within 3 days of completion of study E2020-G000-326 (NCT00478205).
  4. Health: physically healthy and ambulatory or ambulatory-aided (that is, walker or cane); corrected vision and hearing sufficient for compliance with testing procedures.
  5. Co-morbid medical conditions must be well-controlled as determined by the investigator.
  6. Participants undergoing treatment with selective serotonin reuptake inhibitors (SSRIs) may be included, provided that doses are within the approved dose range as specified in the Physician's Desk Reference or local equivalent
  7. Concomitant Medications: Participants undergoing treatment with the following medications may be enrolled in the study provided the following conditions are met: chronic daily benzodiazepine use if doses are stable within an approved dose range; bronchodilator medications for treatment of (COPD) as long as drug is administered via metered dose inhaler within approved dose range; memantine if taken at doses of 20 mg/day or less, provided that the dose is stable.
  8. The participants must have a relative/caregiver who supervises the regular taking of the drug at the correct dose and is alert for possible side effects, unless the participant's legal guardian takes on this task.

Inclusion Criteria for Caregivers. Written informed consent will be obtained from the designated caregiver for participation in study assessments. The caregiver must be sufficiently familiar with the participant (as determined by the investigator) to provide accurate data. Specifically, the caregiver must have sufficient contact with the participant to provide accurate reports of the participant's functioning, must be able to observe for possible adverse events, and must be able to accompany the participant to all visits. It is preferable that the caregiver be the same as in study E2020-G000-326 (NCT00478205). If no replacement caregiver is available who meets the caregiver inclusion/exclusion criteria, the participant must be discontinued from the study.

Exclusion Criteria for Participants:

  1. No caregiver available to meet the inclusion criteria for caregivers.
  2. Participants with any active or clinically-significant conditions affecting absorption, distribution, or metabolism of the study medication (example, inflammatory bowel disease, gastric or duodenal ulcers, hepatic disease, or severe lactose intolerance).
  3. Known plan for elective surgery during the study period that would require general anesthesia and administration of neuromuscular blocking agents, such as succinylcholine, to induce paralysis/muscle relaxation. Minor surgery, such as colonoscopy or cataract surgery, will be permitted as long as it does not require the use of these paralytic agents.
  4. Participants who are unwilling or unable to fulfill the requirements of the study.
  5. Use of any prohibited prior or concomitant medications.
  6. Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study.
  7. Participant taking concomitant antidepressant medication known to have significant anticholinergic effects, such as tricyclic antidepressants prescribed at doses recommended for the treatment of major depression.
  8. Participants who cannot swallow or who have difficulty swallowing whole tablets.
  9. Participants taking any alternative medication such as vitamins and/or herbal products or alternative medical techniques such as acupuncture or acupressure specifically for the treatment of Alzheimer's disease.

Exclusion Criteria for Caregivers.

  1. Caregivers who are unwilling or unable to give informed consent or otherwise to fulfill the requirements of the study.
  2. Any condition that would make the caregiver, in the opinion of the investigator, unsuitable for the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
915 participants (actual)

Study arms

  • Experimental
    Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)

    Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).

    Drug: Donepezil

  • Experimental
    Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)

    Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg immediate release (IR) in the preceding double-blind study E2020-G000-326 (NCT00478205).

    Drug: Donepezil

Interventions

  • Donepezil SR 23 mg once daily orally.

    Also known as: Aricept

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product, a change in treatment, or discontinuation of study drug, recurrence of an intermittent medical condition not present pretreatment, an abnormal laboratory test result was considered an AE if the identified laboratory abnormality led to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not. All AEs in Study 328 (NCT00566501) excluding treatment-emergent signs or symptoms continuing from Study 326 (NCT00478205) were reported.

    Time frame: From the enrollment of the study up to 30 days after last dose of the study drug (up to 2 years 3 months)

Secondary outcomes

  1. Percentage of Participants With at Least 1 Treatment-Emergent Abnormal Laboratory Values (TEAVs): Hematology

    A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range post-dose, but within the normal range prior to drug administration, or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration. Abnormal values for hematology parameters were: White Blood cells count: less than or equal to \[\<=\] 2,800/per millimeter (mm) or greater than or equal to \[\>=\] 16,000/mm; Neutrophils: \<=15 percent (%); Hemoglobin: Male (\<=11.5 gram per deciliter \[g/dL\]), Female (\<=9.5 g/dL); Hematocrit: Male (\<=37%), Female (\<=32%); Eosinophils: \>=10%; Platelet Count: \<=75,000/mm or \>=700,000/mm. Percentage of participants with at least 1 abnormal TEAV for hematology was reported.

    Time frame: From the first dose of study drug up to 2 years 3 months

  2. Percentage of Participants With at Least 1 TEAVs for Selected Parameters: Clinical Chemistry

    A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range postdose, but within the normal range prior to drug administration,or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration.Abnormal values for clinical chemistry parameters were:Sodium:Less than(\<)130 milliequivalents per litre (mEq/L) or greater than(\>)150 mEq/L;Potassium:\<3 mEq/L or \>5.5 mEq/L; Calcium: \<8.4 milligram per deciliter (mg/dL) or \>1.5 mg/dL;Albumin: 50% lower limit of normal (LLN); Alkaline Phosphatase:\>=3\*upper limit of normal (ULN);Aspartate aminotransferase (AST):\>=3\*ULN;Alanine aminotransferase(ALT):\>=3\*ULN;Total Bilirubin:\>=2.0 mg/dL;Chloride:\<90 mEq/L or \>115 mEq/L;Creatinine:\>=2.0 mg/dL;Creatine phosphokinase:\>=3\*ULN;Blood Urea Nitrogen (BUN):\>=30 mg/dL. Percentage of participants with at least 1 abnormal TEAV (selected parameters) for clinical chemistry was reported.

    Time frame: From the first dose of study drug up to 2 years 3 months

  3. Change From Baseline in Severe Impairment Battery (SIB) Total Score

    The SIB evaluated the severity of cognitive dysfunction in participants with more advanced dementia. Test questions measured attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses were allowed, thus decreasing the need for language output. Forty questions were included with a total possible score range of 0-100. Lower scores indicated greater cognitive impairment.

    Time frame: At Baseline, Month 3, Month 6, Month 9 and Month 12

  4. Change From Baseline in Mini-Mental State Examination (MMSE) Total Score

    MMSE is a 30-point scale that measured orientation to time and place, registration, immediate and delayed recall, attention, language, and drawing. Scores ranged from 0 (most impaired) to 30 (no impairment). Lower score indicated more impairment.

    Time frame: At Baseline, Month 3, Month 6, Month 9 and Month 12

  5. Change From Baseline in Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Severe Scale (ADCS-ADL) Total Score

    ADCS-ADL is a comprehensive battery of ADL questions used to measure a participant's functional capabilities. The modified ADCS-ADL-severe scale is a 19-item scale that has been validated for the assessment of participants with moderate to severe dementia. It measured the most appropriate basic and instrumental abilities (such as walking, grooming, bathing, and eating) in this participant population. Response to each item was obtained by interview with the caregiver. Ratings reflected caregiver observations about the participant's actual functioning and provided an assessment of change in the functional state of the participant over time. The total score ranged from 0 to 54. Lower scores indicated greater functional impairment.

    Time frame: At Baseline, Month 3, Month 6, Month 9 and Month 12

  6. Change From Baseline in Quality of Life-Alzheimer's Disease (Qol-AD) Total Score

    QoL-AD is a 13-item quality of life instrument developed to specifically assess QoL in participants who have dementia. Each item was scored on a 4-point scale (poor, fair, good, excellent) and a single score was calculated, ranging from 13 (low functioning) to 52 (normal function). Higher score indicated better QoL. The QoL-AD total scores for the participants and caregiver were the sum of the 13 items on each test.

    Time frame: At Baseline, Month 6 and Month 12

  7. Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Total Score

    EQ-5D is a health profile questionnaire assessing quality of life along 5 domains. Caregivers rated 5 domains of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 to 0. HSI total score ranged from 1 (full health) and 0 (worst health/death).

    Time frame: At Baseline, Month 6 and Month 12

  8. Change From Baseline in Screen for Caregiver Objective Burden (SCB) Total Score

    The SCB is a 25-item instrument that questions caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from "0" (no occurrence) to "4" (occurrence with severe distress). The objective burden was the sum of the total numbers of (1 2 3 4) in all items. Total score ranged from 0 (low distress) to 100 (high distress).

    Time frame: At Baseline, Month 6 and Month 12

  9. Change From Baseline in Screen for Caregiver Subjective Burden (SCB) Total Score

    The SCB is a 25-item instrument that questioned caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from "0" (no occurrence) to "4" (occurrence with severe distress). The subjective burden was the sum of the (total number with score\*score). Total score ranged from 0 (no occurrence) to 100 (occurrence with severe distress).

    Time frame: At Baseline, Month 6 and Month 12

  10. Number of Participants With Treatment Outcome Scale (TOS) Score

    TOS is a pilot instrument designed to evaluate the caregiver's assessment of the participant's status. The caregiver was asked how much he/she thinks the participant has been helped by participating in the study. This instrument comprised a 7-point Likert scale in which a rating of 1=Very much improved; 2=Moderately improved; 3=Minimally improved; 4=About the same; 5=Minimally worse; 6=Moderately worse; 7=Very much worse. The total scale ranged from 1 (marked improvement) to 7 (marked worsening).

    Time frame: At Months 6 and 12

  11. Goal Attainment Scaling (GAtS) Score Total Score

    GAtS is a technique that is standardized with respect to the general approach, but individualized with respect to the outcome goals of each participant. GAtS was designed to provide insight into the changes that are considered as important by the caregiver and (if feasible) by the participants. At study initiation, the participants (if capable) and, separately, the caregiver were asked to specify up to 4 goals for the participants during study participation. For each goal, a description of the current state (or one supplied with the help of the clinician if necessary) was provided to anchor the baseline assessment at 0, and other possible outcomes were described. The outcome for each goal was quantified by a 4-point scale that provided for improvement (+1, +2), no change (0) or worsening (-1, -2). Total score ranged from -30 (worsened) to 130 (most improved). Baseline score was set to be 50 (when scores of all goals are '0' \[no change\]).

    Time frame: At Months 6 and 12

07

Results

Posted Jun 19, 2012

Participant flow

Participants took part in the study at 179 centers in Asia, Europe, North America, Oceania, South Africa, and South America during 14 December 2007 to 01 April 2010. This study E2020-G000-328 (NCT00566501) was a 12-month, open-label extension of study E2020-G000-326 (NCT00478205). Participants who had received donepezil 10 milligram (mg) immediate release (IR) or donepezil 23 mg sustained release (SR) during Study E2020-G000-326 (NCT00478205) were eligible for enrollment into this study.

Participant flow — Overall Study
MilestoneDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Started570332
Completed423210
Not completed147122
Withdrew: Adverse event6859
Withdrew: Medication non-compliance50
Withdrew: Protocol violation22
Withdrew: Request of investigator or sponsor67
Withdrew: Withdrawal by subject3330
Withdrew: Lack of efficacy83
Withdrew: Other2521

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the investigational product, a change in treatment, or discontinuation of study drug, recurrence of an intermittent medical condition not present pretreatment, an abnormal laboratory test result was considered an AE if the identified laboratory abnormality led to any type of intervention, withdrawal of study drug, or withholding of study drug, whether prescribed in the protocol or not. All AEs in Study 328 (NCT00566501) excluding treatment-emergent signs or symptoms continuing from Study 326 (NCT00478205) were reported.

Time frame:
From the enrollment of the study up to 30 days after last dose of the study drug (up to 2 years 3 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Number of Participants With Adverse Events (AEs)416259
SecondaryPercentage of Participants With at Least 1 Treatment-Emergent Abnormal Laboratory Values (TEAVs): Hematology

A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range post-dose, but within the normal range prior to drug administration, or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration. Abnormal values for hematology parameters were: White Blood cells count: less than or equal to \[\<=\] 2,800/per millimeter (mm) or greater than or equal to \[\>=\] 16,000/mm; Neutrophils: \<=15 percent (%); Hemoglobin: Male (\<=11.5 gram per deciliter \[g/dL\]), Female (\<=9.5 g/dL); Hematocrit: Male (\<=37%), Female (\<=32%); Eosinophils: \>=10%; Platelet Count: \<=75,000/mm or \>=700,000/mm. Percentage of participants with at least 1 abnormal TEAV for hematology was reported.

Time frame:
From the first dose of study drug up to 2 years 3 months
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Treatment-Emergent Abnormal Laboratory Values (TEAVs): Hematology
percentage of participantsDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Percentage of Participants With at Least 1 Treatment-Emergent Abnormal Laboratory Values (TEAVs): Hematology9.510.9
SecondaryPercentage of Participants With at Least 1 TEAVs for Selected Parameters: Clinical Chemistry

A TEAV for a laboratory parameter was defined as a value that was clinically significantly outside (above or below) the normal range postdose, but within the normal range prior to drug administration,or a value that represented a clinically significant exacerbation of an abnormality present prior to drug administration.Abnormal values for clinical chemistry parameters were:Sodium:Less than(\<)130 milliequivalents per litre (mEq/L) or greater than(\>)150 mEq/L;Potassium:\<3 mEq/L or \>5.5 mEq/L; Calcium: \<8.4 milligram per deciliter (mg/dL) or \>1.5 mg/dL;Albumin: 50% lower limit of normal (LLN); Alkaline Phosphatase:\>=3\*upper limit of normal (ULN);Aspartate aminotransferase (AST):\>=3\*ULN;Alanine aminotransferase(ALT):\>=3\*ULN;Total Bilirubin:\>=2.0 mg/dL;Chloride:\<90 mEq/L or \>115 mEq/L;Creatinine:\>=2.0 mg/dL;Creatine phosphokinase:\>=3\*ULN;Blood Urea Nitrogen (BUN):\>=30 mg/dL. Percentage of participants with at least 1 abnormal TEAV (selected parameters) for clinical chemistry was reported.

Time frame:
From the first dose of study drug up to 2 years 3 months
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 TEAVs for Selected Parameters: Clinical Chemistry
percentage of participantsDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Percentage of Participants With at Least 1 TEAVs for Selected Parameters: Clinical Chemistry14.313.1
SecondaryChange From Baseline in Severe Impairment Battery (SIB) Total Score

The SIB evaluated the severity of cognitive dysfunction in participants with more advanced dementia. Test questions measured attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses were allowed, thus decreasing the need for language output. Forty questions were included with a total possible score range of 0-100. Lower scores indicated greater cognitive impairment.

Time frame:
At Baseline, Month 3, Month 6, Month 9 and Month 12
Reported as:
Mean · score on a scale
Change From Baseline in Severe Impairment Battery (SIB) Total Score
score on a scaleDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
At Baseline78.4 ± 19.0577.2 ± 19.49
Change at Month 3-1.7 ± 7.11-0.9 ± 6.55
Change at Month 6-4.0 ± 9.52-2.8 ± 8.68
Change at Month 9-5.5 ± 11.19-5.2 ± 9.71
Change at Month 12-7.5 ± 12.99-6.7 ± 10.75
SecondaryChange From Baseline in Mini-Mental State Examination (MMSE) Total Score

MMSE is a 30-point scale that measured orientation to time and place, registration, immediate and delayed recall, attention, language, and drawing. Scores ranged from 0 (most impaired) to 30 (no impairment). Lower score indicated more impairment.

Time frame:
At Baseline, Month 3, Month 6, Month 9 and Month 12
Reported as:
Mean · score on a scale
Change From Baseline in Mini-Mental State Examination (MMSE) Total Score
score on a scaleDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Baseline14.1 ± 5.8113.8 ± 6.02
Change at Month 3-0.6 ± 2.27-0.5 ± 2.20
Change at Month 6-1.3 ± 2.70-1.2 ± 2.53
Change at Month 9-1.7 ± 2.95-1.7 ± 2.77
Change at Month 12-2.3 ± 3.08-2.1 ± 3.04
SecondaryChange From Baseline in Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Severe Scale (ADCS-ADL) Total Score

ADCS-ADL is a comprehensive battery of ADL questions used to measure a participant's functional capabilities. The modified ADCS-ADL-severe scale is a 19-item scale that has been validated for the assessment of participants with moderate to severe dementia. It measured the most appropriate basic and instrumental abilities (such as walking, grooming, bathing, and eating) in this participant population. Response to each item was obtained by interview with the caregiver. Ratings reflected caregiver observations about the participant's actual functioning and provided an assessment of change in the functional state of the participant over time. The total score ranged from 0 to 54. Lower scores indicated greater functional impairment.

Time frame:
At Baseline, Month 3, Month 6, Month 9 and Month 12
Reported as:
Mean · score on a scale
Change From Baseline in Modified Alzheimer's Disease Cooperative Study Activities of Daily Living Severe Scale (ADCS-ADL) Total Score
score on a scaleDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Baseline34.3 ± 11.2634.3 ± 11.26
Change at Month 3-1.6 ± 5.30-1.8 ± 5.27
Change at Month 6-3.2 ± 6.13-3.7 ± 6.53
Change at Month 9-4.6 ± 6.91-4.8 ± 7.46
Change at Month 12-5.6 ± 7.62-6.8 ± 8.96
SecondaryChange From Baseline in Quality of Life-Alzheimer's Disease (Qol-AD) Total Score

QoL-AD is a 13-item quality of life instrument developed to specifically assess QoL in participants who have dementia. Each item was scored on a 4-point scale (poor, fair, good, excellent) and a single score was calculated, ranging from 13 (low functioning) to 52 (normal function). Higher score indicated better QoL. The QoL-AD total scores for the participants and caregiver were the sum of the 13 items on each test.

Time frame:
At Baseline, Month 6 and Month 12
Reported as:
Mean · score on a scale
Change From Baseline in Quality of Life-Alzheimer's Disease (Qol-AD) Total Score
score on a scaleDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Caregiver; Baseline31.6 ± 6.3730.8 ± 6.62
Caregiver; Change at Month 6-1.4 ± 5.17-1.4 ± 5.08
Caregiver; Change at Month 12-1.8 ± 5.60-1.8 ± 5.28
Participant; Baseline35.2 ± 6.6534.5 ± 6.90
Participant; Change at Month 6-0.2 ± 5.10-0.1 ± 4.95
Participant; Change at Month 12-0.2 ± 5.02-0.2 ± 4.76
SecondaryChange From Baseline in European Quality of Life-5 Dimension (EQ-5D) Total Score

EQ-5D is a health profile questionnaire assessing quality of life along 5 domains. Caregivers rated 5 domains of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The EQ-5D Health Utilities Index (HUI) is derived from the five dimensions of the EQ-5D, using country-specific preference weights (tariffs) to summarize how good or bad each health state is on a scale from 1 to 0. HSI total score ranged from 1 (full health) and 0 (worst health/death).

Time frame:
At Baseline, Month 6 and Month 12
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Total Score
score on a scaleDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Baseline0.76 ± 0.170.77 ± 0.19
Change at Month 6-0.04 ± 0.15-0.04 ± 0.18
Change at Month 12-0.06 ± 0.18-0.06 ± 0.19
SecondaryChange From Baseline in Screen for Caregiver Objective Burden (SCB) Total Score

The SCB is a 25-item instrument that questions caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from "0" (no occurrence) to "4" (occurrence with severe distress). The objective burden was the sum of the total numbers of (1 2 3 4) in all items. Total score ranged from 0 (low distress) to 100 (high distress).

Time frame:
At Baseline, Month 6 and Month 12
Reported as:
Mean · score on a scale
Change From Baseline in Screen for Caregiver Objective Burden (SCB) Total Score
score on a scaleDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Baseline9.8 ± 4.369.8 ± 4.74
Change at Month 60.5 ± 3.761.0 ± 3.64
Change at Month 121.2 ± 3.941.5 ± 3.98
SecondaryChange From Baseline in Screen for Caregiver Subjective Burden (SCB) Total Score

The SCB is a 25-item instrument that questioned caregivers about the occurrence and degree of distress as aspects of the burden of care during the preceding two weeks. It was designed specifically for use with caregivers of Alzheimer's disease participants. Each item was assessed on a 5-point scale ranging from "0" (no occurrence) to "4" (occurrence with severe distress). The subjective burden was the sum of the (total number with score\*score). Total score ranged from 0 (no occurrence) to 100 (occurrence with severe distress).

Time frame:
At Baseline, Month 6 and Month 12
Reported as:
Mean · score on a scale
Change From Baseline in Screen for Caregiver Subjective Burden (SCB) Total Score
score on a scaleDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Baseline18.4 ± 10.9818.5 ± 12.14
Change at Month 61.7 ± 10.033.0 ± 9.63
Change at Month 123.2 ± 10.304.3 ± 10.64
SecondaryNumber of Participants With Treatment Outcome Scale (TOS) Score

TOS is a pilot instrument designed to evaluate the caregiver's assessment of the participant's status. The caregiver was asked how much he/she thinks the participant has been helped by participating in the study. This instrument comprised a 7-point Likert scale in which a rating of 1=Very much improved; 2=Moderately improved; 3=Minimally improved; 4=About the same; 5=Minimally worse; 6=Moderately worse; 7=Very much worse. The total scale ranged from 1 (marked improvement) to 7 (marked worsening).

Time frame:
At Months 6 and 12
Reported as:
Count of participants · Participants
Number of Participants With Treatment Outcome Scale (TOS) Score
ParticipantsDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
At Month 6 — 1=Very much improved107
At Month 6 — 2=Moderately improved5629
At Month 6 — 3=Minimally improved6640
At Month 6 — 4=About the same14979
At Month 6 — 5=Minimally worse13073
At Month 6 — 6=Moderately worse9657
At Month 6 — 7=Very much worse2317
At Month 12 — 1=Very much improved125
At Month 12 — 2=Moderately improved3720
At Month 12 — 3=Minimally improved6723
At Month 12 — 4=About the same9152
At Month 12 — 5=Minimally worse10342
At Month 12 — 6=Moderately worse8954
At Month 12 — 7=Very much worse4126
SecondaryGoal Attainment Scaling (GAtS) Score Total Score

GAtS is a technique that is standardized with respect to the general approach, but individualized with respect to the outcome goals of each participant. GAtS was designed to provide insight into the changes that are considered as important by the caregiver and (if feasible) by the participants. At study initiation, the participants (if capable) and, separately, the caregiver were asked to specify up to 4 goals for the participants during study participation. For each goal, a description of the current state (or one supplied with the help of the clinician if necessary) was provided to anchor the baseline assessment at 0, and other possible outcomes were described. The outcome for each goal was quantified by a 4-point scale that provided for improvement (+1, +2), no change (0) or worsening (-1, -2). Total score ranged from -30 (worsened) to 130 (most improved). Baseline score was set to be 50 (when scores of all goals are '0' \[no change\]).

Time frame:
At Months 6 and 12
Reported as:
Mean · score on a scale
Goal Attainment Scaling (GAtS) Score Total Score
score on a scaleDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Caregivers; At Month 6-2.6 ± 9.63-3.2 ± 9.97
Caregivers At Month 12-5.1 ± 11.10-5.9 ± 10.61
Participants; At Month 62.2 ± 7.34-0.8 ± 8.26
Participants; At Month 122.4 ± 7.89-0.6 ± 9.57

Adverse events

Collected over From the first dose of study drug up to 2 years 3 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)14/570 (2.5%)80/570 (14%)415/570 (72.8%)
Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)5/332 (1.5%)56/332 (16.9%)259/332 (78%)
Most frequent serious events
Showing 10 of 136
Most frequent serious events
EventDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
SyncopeNervous system disorders6/5706/332
Urinary tract infectionInfections and infestations8/5703/332
FallInjury, poisoning and procedural complications7/5702/332
Mental status changePsychiatric disorders0/5704/332
pneumoniaInfections and infestations6/5701/332
Subdural haematomaInjury, poisoning and procedural complications1/5703/332
DehydrationMetabolism and nutrition disorders2/5703/332
Transient ischemic attackNervous system disorders1/5703/332
AggressionPsychiatric disorders1/5703/332
InsomniaPsychiatric disorders0/5703/332
Most frequent other events
Showing 10 of 29
Most frequent other events
EventDonepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)
Weight decreasedInvestigations58/57043/332
FallInjury, poisoning and procedural complications54/57025/332
AgitationPsychiatric disorders33/57028/332
AggressionPsychiatric disorders29/57023/332
Urinary tract infectionRenal and urinary disorders33/57020/332
NauseaGeneral disorders12/57020/332
DiarrhoeaGastrointestinal disorders20/57019/332
InsomniaGastrointestinal disorders18/57015/332
VomitingGastrointestinal disorders9/57015/332
DepressionPsychiatric disorders15/57012/332

Baseline characteristics

The safety population included all participants who received at least one dose of the study medication during the open-label treatment period and had at least one post-baseline safety assessment.

Age, Continuous
Age, Continuous(years)Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)Total
Mean74.1 ± 8.6774.5 ± 8.4474.3 ± 8.58
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)Total
Female373202575
Male197130327
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)Total
Black16723
White429245674
Hispanic421860
Asian/Pacific8060140
Other325
08

Study locations

1 site
  • Apex Research Institute
    Santa Ana, California 92705, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2007 to primary completion in Apr 2010, 27 months.

Results were first posted in Jun 2012, 2 years 2 months after primary completion.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 27 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2007
First posted
Dec 3, 2007
StartActual
Dec 14, 2007
Primary completionActual
Apr 1, 2010
CompletionActual
Apr 1, 2010
Results first posted
Jun 19, 2012
Last update
Nov 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00566501
Lead sponsor
Eisai Inc.
Collaborators
Eisai Limited
Responsible party
Sponsor
First posted
Dec 3, 2007
Start date
Dec 14, 2007
Primary completion
Apr 1, 2010
Completion
Apr 1, 2010
Results posted
Jun 19, 2012
Last update
Nov 17, 2021

Study contacts

Jane Yardley, Ph.D
study director · Eisai Limited

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion